Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
overall response rate
time to disease progression
progressive disease-free interval
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope Natioal Medical Center
Duarte, California, United States
Scripps Memorial Hospital
La Jolla, California, United States
UCSD Stem Cell Laboratory
La Jolla, California, United States
Hoag Hospital
Newport Beach, California, United States
Sutter Cancer Center
Sacramento, California, United States
Sidney Kimmel Cancer Center
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Stanford University Medical Center
Stanford, California, United States
Kaiser Permanente Medical Center
Vallejo, California, United States
...and 21 more locations